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There are increasing calls to decolonise aspects of science, and global health is no exception. The decolonising
global health movement acknowledges that global health research perpetuates existing power imbalances and
aims to identify concrete ways in which global health teaching and research can overcome its colonial past
and present. Using the context of clinical trials implemented through transnational research partnerships (TRPs)
as a case study, this narrative review brings together perspectives from clinical research and social science to
lay out specific ways in which TRPs build on and perpetuate colonial power relations. We will explore three core
components of TRPs: participant experience, expertise and infrastructure, and authorship. By combining a critical
perspectivewith recently published literaturewewill recommend specificways inwhich TRPs can be decolonised.
We conclude by discussing decolonising global health as a potential practice and object of research. By doing this
we intend to frame the decolonising global health movement as one that is accessible to everyone and within
which we can all play an active role.
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Introduction
There are increasing calls to decolonise aspects of science, and
global health is no exception. What it means to decolonise global
health is not always well explained or understood and to some
the act itself may seem too ill-defined, obscure or daunting for
it to be achievable. Using the context of clinical trials conducted
through transnational research partnerships (TRPs) as a case
study, the purpose of this article is to demonstrate that a multi-
disciplinary approach, combining the practical experience of a re-
search physician with the critical perspective of a social scientist,
can be applied to critique aspects of global health research. We
will draw particularly on experience from the continent of Africa,
but aspects of this review will apply to broader contexts. We fo-
cus particularly on randomised controlled trials, which are, de-
spite criticism,1,2 regarded as producing the most rigorous data
for an intervention and, possibly because of this, where TRPs are
commonly found. Specifically, we historicise and contextualise
three aspects of TRPs (participant experience, expertise and in-
frastructure, and authorship) to lay out specific ways in which
TRPs build on and perpetuate colonial power relations before
suggesting specific ways in which we can work towards more
equitable TRPs. By doing this, we intend to frame the decolonis-
ing global health movement as one that is accessible to every-
one and within which we can and should all play an active role.
We refrain here from offering a normative or static definition
of what decolonising global health means and accept, follow-
ing Tuck and Yang,3 that real decolonisation needs to take place
outside academia and needs to be led and abide by the princi-
ples of indigenous communities. Although we primarily focus on
decolonisation, we also recognise the intersectional vulnerabili-
ties that disproportionately affect women and junior researchers
(of colour) within global health.4
The decolonising global health movement
When working in the field of global health research one is con-
stantly exposed to, and even complicit in, the power imbalances
that exist between researchers in high-income countries (HICs),
researchers in low- andmiddle-income countries (LMICs) and the
research participants we work with.5 These inequalities largely
derive from colonialism and are frequently the subject of debate
within the field.6 Indeed, the very notion of global health and
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global health research have been subject to the label of ‘scien-
tific colonialism’.6,7 Against this background, various ‘decolonis-
ing global health’ (DGH) movements have emerged at universi-
ties in the last few years.8–10 Importantly, these movements are
often student-led and include high proportions of students from
LMICs and their diasporas. Where we work, at the London School
of Hygiene and Tropical Medicine, the DGHmovement has started
exploring concrete ways in which global health teaching and re-
search can overcome its colonial past in terms of representation,
research and funding processes. These movements, which have
emerged predominantly within universities in the Global North,
are only one of many manifestations that critiques of our current
global health system have taken. As pointed out by DGH move-
ments, we have to bemindful to listen to and learn from the peo-
ple at the receiving end of global health interventions. In this ar-
ticle we want to draw on the important and innovative work of
the DGHmovement to think through and provide suggestions for
the decolonisation of TRPs.4
The importance of global health research
Clinical trials generate important knowledge and there is a need
for well-conducted clinical trials to take place in sub-Saharan
Africa. In fact, there has been long-standing criticism surround-
ing the general neglect of the region in terms of clinical research.
Roughly 80% of all clinical trials are conducted in HICs11 and
diseases of relevance to HICs are investigated in clinical trials
seven to eight times more often than those whose burden lies
in LMICs.12 Criticism continues concerning the representation of
different populations in research and this is exemplified by the
disproportionately low number of individuals from LMICs who are
recruited into clinical trials, despite the often higher burden of
disease.13 For example, one review found that in the context of
human immunodeficiency virus (HIV), only 31% of all preven-
tion or treatment trials prior to 2009 were conducted in LMICs
despite these countries representing 99% of the mortality as-
sociated with HIV infection.14 The underrepresentation of LMIC
populations in medical trials, apart from being seemingly unfair,
has important consequences for how we understand and mea-
sure health. Biomedical interventions in LMICs have, since the ad-
vent of tropicalmedicine, relied on the assumption that European
white bodies are the normative gauge of health.15 Aswithwomen
and children, who have historically been excluded from medical
trials,16,17 the exclusion of diverse, non-European bodies impacts
who treatments andmedications are designed for and is likely to
disadvantage the health of non-white European male bodies.18
Research in LMICs is therefore essential but must be designed to
benefit the local population. Foreign characterisations of LMICs as
suitable locations for high-risk or ethically dubious research that
can benefit individuals in HICs, as was recently proposed by re-
searchers trialling a coronavirus vaccine, must be rejected.19
Transnational research partnerships
Clinical trials in LMICs are most commonly conducted through
TRPs. These are cooperative pieces of research conducted by a
combination of research institutions from different countries. In
the context of global health, these partnerships are almost al-
ways between institutions in both LMICs and HICs. The premise
of these partnerships is that institutions can collectively pool ex-
pertise, infrastructure and resources to deliver a high-quality out-
come. The number of partnersmay be as small as two, but can be
much larger. In an attempt to quantify the scale of these partner-
ships, a study from 2005 identified all published HIV treatment
and prevention trials conducted in sub-Saharan Africa between
1987 and 2003 and focused on funding, geographical reach and
authorship.20 A total of 77 published trials that recruited patients
from across 18 countries were included. The main funders were
government agencies outside of Africa in 56% of trials and the
pharmaceutical industry provided either full or partial funding to
44%. Funding from African government or non-governmental or-
ganisations contributed to 5 of 77 trials but were not the sole
funders of any. In addition, this review found that the chief in-
vestigator was resident in Africa in only 25% of the trials, with
the majority being from outside the continent, including the USA
(30%) and the UK (10%), among other countries. An update to
this work reported more recent trials conducted between 2004
and 2008 and identified no notable change in these trends over
time.21 These geographical dimensions highlight the continued
dependence of Africanmembers of TRPs on countries and institu-
tions in theGlobal North.Wenow turn to analyse this dependence
in more detail using the examples of participant experience,
expertise and infrastructure, and authorship.
Analysis
The participant experience
Clinical trials are only possible thanks to the willing participation
of research participants and they should be at the centre of all de-
bate and discussion. To date, there exists no published research
that has specifically explored the perspective of participants in
LMICs when it comes to the structure of global health research.
During clinical trials administered through TRPs, research partic-
ipants are not directly asked for their thoughts on this subject.
Here we aim to provide two examples that shed light on how the
experience of clinical trials in sub-Saharan Africa is permeated
by colonial history and colonial power relations: rumours and
informed consent.
A large portion of the ethnographic work exploring partici-
pant experience of research in LMICs has elicited data concern-
ing rumours, most commonly in the context of blood stealing.
In East and Central Africa, the historical basis for such rumours
has been linked to the violent and extractive practices of colo-
nial medical officers in the 19th and 20th centuries.22 Today
these rumours may be dismissed as expressions of ignorance or
simply as being related to ‘culture’, but numerous social scien-
tists have described them as forms of popular resistance.23–25
In research within healthy volunteer studies, the generation of
rumours about research studies and institutions is particularly
prevalent when poor outcomes such as severe disability or death
occur and, even in the absence of any clear link to the research
study, there is often an apportioning of blame. These rumours
often contain local interpretations of medical research ethics, es-
pecially related to the problems of resource transfers and flows of
value. It has been argued that rather than ignoring rumours, en-
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and improve relations between medical researchers and study
communities.25
Although the phenomenological interpretations of rumours
provide an important window into the perspectives of research
participants, further research exploring their experience of trials
administered through TRPs is required. Individuals ought to be
given the opportunity to articulate directly their perspective of
how clinical trials are conducted rather than solely being inter-
preted from other observations (most commonly those of for-
eign researchers). This will also be enhanced by increased diver-
sity within research teams and locally-led research protocols that
can effectively elicit and accurately interpret research findings.
It is beyond the scope of this article to outline all the ways
in which international research standards may not suit partic-
ular contexts, and in-depth research has been published else-
where,26,27 but let us now briefly turn to one example of informed
consent. Informed consent, a product and signifier of conduct-
ing ethical research according to European standards, often falls
short of successfully translating into varied research contexts
outside of Europe and North America. As it is, we continue to fall
short of ensuring a full and equivalent understanding of what giv-
ing consent means in the context of TRPs. These issues are mag-
nified by the increase in genetic analyses taking placewithin trials
and the storage of geneticmaterial that often takes place outside
the countries in which clinical trials occur.28,29 There are already
documented cases of research misconduct and exploitation in
this field.29,30 Further research is essential to understandhowpar-
ticipants experience and interpret research ethics in a changing
world.
Expertise and infrastructure
In the context of HIV research, particularly concerning HIV treat-
ment and prevention, large, multisite trials are often conceived
and designed by international research networks based in HICs.
These groups then subsequently identify country leads at each
site who they will then work with to recruit and train teams of re-
searchers for that specific site. In these cases, protocol develop-
ment, the design of standard operating procedures, trial oversight
and data management often occur remotely to the sites, which
means that local researchers implement the trial but do not nec-
essarily gain the skills required to later run their own trials.31
In addition, most research studies involve increasingly complex
analyses of specimens—for example, genetic analysis, which can
only currently be performed in a limited number of state-of-the-
art laboratories that aremost often found outside of sub-Saharan
Africa. The location of medical infrastructures is hugely impor-
tant, because infrastructures are often needed to turn knowledge
into expertise and capacity, both ofwhich are requirements for in-
dividual career progression. They are also necessary to attract fu-
ture funding and the leadership of clinical trials. Over time, the de-
velopment of advanced laboratory infrastructure in some LMICs
has increased their competitiveness when it comes to clinical
research.32
There is huge promise in TRPs, but there is also significant po-
tential to create and perpetuate power imbalances both between
and within individual institutions. Most commonly, chief investi-
gators based in HICs apply to funding bodies, also often based
in HICs, and collectively steer the research agenda in one direc-
tion or another. These researchers are typically employed by re-
search institutions from HICs who measure the performance of
their staff based on research funding andpublications,whichmay
distract them from themore subjective outputs of capacity build-
ing.7 If these strategic funding decisions are not made in consul-
tation with local researchers, there is a potential to overlook the
most pressing research questions for the population as well as
the opportunity to build capacity in that country.33 The most ex-
treme forms of this type of work are exemplified in the frequent
reports of ‘fly-in, fly-out’ or ‘parasitic’ researchers who parachute
into LMICs for short periods of time to collect data and samples
before returning home to publish their findings, often bypassing
local researchers and research needs entirely and, according to
one focus group discussion, leaving institutions feeling like ‘poor
prostitutes’.34–36
Funding of clinical trials is hugely influential and there are
examples of best practice whereby funding is channelled to re-
searchers and institutions based in sub-Saharan Africa, with a fo-
cus not just on research outputs, but on institutional and indi-
vidual capacity building. The European and Developing Countries
Clinical Trials Partnership (EDCTP) is a notable example here.37 The
EDCTP funds clinical trials that address the most pressing public
health needs within a country or region, while also providing ad-
ditional funding to build capacity within research institutions. This
approach requires a significant investment of time and resources,
but such a model could create a future wherein TRPs occur solely
between African institutions. South–South TRPs have been made
more difficult given the slashing of health budgets of countries in
the Global South through structural adjustment programmes in
the 1980s and 1990s.38 Going forward and where possible, gov-
ernments need to integrate research funding into their health-
care budgets while balancing the demand to provide healthcare
services with immediate benefits. Member states of the African
Union, through the Africa Health Strategy 2007–2015, have com-
mitted to allocating 2% of their healthcare budget to research.39
Although a situational analysis of this programme in 2017 found
that target had not been met, this commitment was renewed
in the Health Research and Innovation Strategy for Africa 2018–
2030.40
The way in which success is quantified in global health re-
search also needs to change. When individual performance is
based on successful grant applications and authorship, this dis-
tracts from other meaningful outputs, such as mentorship and
capacity building. International researchers are therefore, often
understandably, guilty of prioritising their own research outputs
rather than helping to develop the skills of their colleagues, which
is an equally constructive and oftenmoremeaningful use of time.
Therefore funders and research institutions need to place greater
emphasis on this work in their appraisal of individuals or risk per-
petuating the idea of research as a white male domain.41
Authorship
Another way to explore how TRPs disproportionately benefit re-
searchers in the Global North is to look at authorship. The num-
ber of first or final author papers that an individual has is used to
gauge their prominence in the field and is often the first port-of-
call for funding bodieswhen reviewing a grant application or insti-











complex and there exist established guidelines that outline what
constitutes an author or a contributor to a piece of research. In
large clinical trials that employ hundreds of staff it is often impos-
sible to list each individual, particularly when some journals place
a limit on the number of authors, although this is less common
than it used to be.42 Including only individuals meeting the defi-
nition of an author may technically be fair and author positioning
may be a true reflection of the workload undertaken and the ‘sci-
entific input’ provided, however, it highlights further that the ben-
eficiaries of global health research are often those based in high-
income institutions. As recent studies have shown, researchers
from LMICs are often ‘stuck in themiddle’ when it comes to global
health authorship resulting from international partnerships, fur-
ther widening the divide between those researchers who benefit
from TRPs (predominantly white and European or North Ameri-
can) and thosewhodo not.43,44 Abimbola’s recent editorial on the
foreign gaze in global health authorshipmakes an equally impor-
tant point.45 He explains the difference between the foreign and
local gaze and asks us to question what the foreign gaze actually
contributes to a holistic understanding of health in LMICs. These
are deeply necessary questions and conversations to have and to
which we hope to contribute here.
In addition, there is evidence suggesting that global health
research is impacted by guest authorship, which is adding au-
thors who did not contribute substantially to the work, and ghost
authorship, which is omitting authors who have contributed
substantially to the work. A survey and interview–based study
solicited responses from researchers based in LMICs who were
presented with various scenarios about authorship, redundant
publication, plagiarism and conflict of interest and asked for
their opinions and experiences of each.46 In this study, 77% of
participants reported the use of guest authorship in their insti-
tution and 41% reported occurrences of ghost authorship. There
is not currently enough evidence to truly determine whether
this is more common in global health research than in any other
discipline, although this has been suggested,47 and no truly com-
parative work has been done in high-income settings to enable a
fair comparison. However, this does demonstrate a widespread
unfairness in how academic work is recognised in this setting.
Authorship will always be important in research, but it is vital
to factor in the contribution made by all parties and advocate for
joint authorship and themost inclusive authorship policy possible,
ensuring that any scientific contribution, no matter how small, is
recognised. In addition, the roles that result in the more presti-
gious authorship positions need to be available and accessible to
a more diverse group of researchers. We must also recognise to
what extent we, as researchers and practitioners from or based
in the Global North, have benefitted from a global health system
built on colonial medicine, which continues to replicate colonial
power dynamics in infrastructure, expertise and authorship.
Discussion
Decolonising TRPs
How can one work towards decolonising TRPs that, at their core,
further dependence? Should we be speaking of partnerships at
all? Surely the aim of decolonising TRPs should be to negate the
need, motivation or opportunity for certain individuals and in-
stitutions to be involved at all. There are significant aspects of
global health research that need to change and this is a process
that needs to take place over time, rather than overnight, so as
not to jeopardise the real benefits to health that result from this
research. And it should start now.
We all have a responsibility to create an open environment
whereby it is safe to discuss this issue. It is often easier for re-
searchers in HICs to discuss neo-colonial aspects of global health
research but it is far more intimidating for the majority of African
researchers to do the same, particularly among their interna-
tional collaborators. This reluctance is yet another colonial as-
pect of global health. There are intellectual decolonisationmove-
ments occurring across Africa, with the University of Cape Town
being a notable example. But within TRPs there is a need for
spaces and forums for debate across the continent where African
and international researchers are able to have frank, open discus-
sions about these power imbalances and develop solutions going
forward. International researchers also need to embrace what is
often an inconvenient truth. The London School of Hygiene and
Tropical Medicine, where wework, hasmade a start in this regard,
forming a working group that is exploring the school’s historical
links to colonialism and exploring how a world-renowned aca-
demic institution can undergo transformation. But each setting
is nuanced and these conversations are required at the country
and institutional level.
Working on the assumption that TRPs will not disappear
overnight and that international researchers are likely to remain
engaged in research in Africa for some time, it becomes impor-
tant to focus on how they navigate through this space. This is
increasingly relevant, as the trend seems to be for institutions
in HICs to increasingly build links with those in LMICs. Interna-
tional researchers are a heterogeneous group, some of whomare
respectful of institutional culture and reflective on their position
within it, whereas others are less so. We all need to be culturally
and racially literate when it comes to global health research and
this needs to happen as early in our careers as possible. Medi-
cal schools and research institutions have a duty to generate dis-
cussion concerning the complexity of global health research and
to develop, in partnership with their collaborators, guidelines for
the responsible conduct of research in LMICs. It is not acceptable
for researchers to assume that because they are from an inter-
national institution that they are more knowledgeable, that their
work should take priority or that they deserve the premium posi-
tion on papers. This is a particular risk when individuals are new to
the researchworld or the country inwhich they are conducting re-
search. A prolonged, sustained period of conducting research in a
country will always be far preferable to a fly-in, fly-out approach.
Research and decolonisation
There is a need for further research into TRPs. With an increased
appreciation of the potential harms and benefits of TRPs there is
an urgent need for an exploration of their impact on all stake-
holders. This includes ongoing quantification and monitoring of
key indicators related to the three domains we have discussed as
well as in-depth qualitative studies. In particular, no previous orig-
inal research exploring TRPs from the perspective of researchers
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understand how research participants themselves experience the
research process within these partnerships. This is the partial fo-
cus of an ongoing ethnographic study being conducted by D. S.
Lawrence and colleagues (ClinicalTrials.gov: NCT04296292).
There is also a need to focus on decolonisation as the sub-
ject of research. Any research into this topic needs to be carefully
planned to ensure that it does not (re)create the existing power
imbalances and biases it is trying to address and is aware of its
limitations.We all need to do thework tomake global health truly
global. This means giving voice to the global majority in global
health authorship, listening to the experiences of research partic-
ipants and making sure that clinical trials increasingly take place
in the countries and regions whose health problems they work
to alleviate. First and foremost, it means checking our own privi-
lege and realising that as practitioners and researchers based in
and affiliated with institutions in the Global North, we continue
to benefit from a global health system built on colonial medicine.
All research and commentary will be restricted by the lived ex-
perience of the individual researchers, this article included. De-
colonising global health presents an opportunity to make global
health more inclusive and work towards health justice. Let’s get
to it.
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